StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Observations on the PR 1 Oct 2024

<< Previous

Bullboard Posts

Next >>

Comment by Nailbiter2on Nov 21, 2024 5:38pm

24 Views

Post# 36324852

RE:RE:Observations on the PR 1 Oct 2024

Nailbiter2 wrote:
IainCaimbeul wrote: “This first half of 2024 has been a very different period for us..." Different how? Seems to me it's just a continuation of the freefall since Aristotle was "launched" in 2021.

“Key now, is to launch into our strategic partnerships to fuel the uptake of our Aristotle..." Partnerships. Have I heard this one before? Oh yeah numerous times with zero results, show me the money JTH.

"The Company has been under a failure to file cease trade order (“FFCTO”) since April 9, 2024. During that time operations have been ongoing, disclosure has continued,..." "Disclosure has continued" is code for we will keep shareholders in the dark and tell them nothing, will not give a meaningful (if any) reply to emails from shareholders.

"The Company’s laboratory has been relocated in Richmond, VA to a more suitable space. Translation: we could not afford the old location because of falling revenues, so we had to do a downsizing.

"New partnerships have been brought on,..." Oh, name me ONE.

"The Company anticipates additional partnerships and..." Have been hearing this one for years now with zero results.

"The Company is diligently continuing its efforts to have sufficient funds to fully pay the auditors. It anticipates having them paid by October 30th,..." Oops, missed that one - again. But don't forget Becky told one of pumpers we are working hard.

"The Company anticipates filing the Q3 financials on time, by November 14, 2024...." Oopsie, missed that one also, they did not even make an attempt to explain why.

To summarize: Stagezero reduced lab space when they are supposed to be expanding operations, stopped "selling" Aristotle while downsizing lab space, fired staff, missed another "deadline" to pay the auditors, added phantom partners, have gone into zero disclosure mode, managed to further drop revenues. Did I miss anything?

Make Aristotle Great Again.